Rigel Pharmaceuticals, Inc. RIGL
Set alert
At close · Oct 30
After hours · Oct 30, 6:58 PM ET
- YTD
- +19.80%
- 1 year
- +62.27%
- Open
- 51.80
- Prev close
- 51.45
- Mkt cap
- 949.34M
- Vol
- 174.41K
- Avg vol
- 260.05K
- EPS
- 16.88
- P/E
- 3.04
- Div yield
- 0.00%
More statistics
- Low
- 50.67
- High
- 52.61
- Forward P/E
- 19.49
- Beta
- 0.95
- Short ratio
- 1.69
- Inst. own
- 68.01%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 20.01
- 200-d avg
- 13.77
- 1y target
- 31.33
5D chart
Signals (112)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:00 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:25 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:05 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:05 AM | 6 days ago |
| SMA: Bullish | Oct 23, 3:25 PM | 1 week ago |
| MACD: Buy Signal | Oct 23, 3:25 PM | 1 week ago |
| SMA: Bearish | Oct 23, 3:05 PM | 1 week ago |
| SMA: Bullish | Oct 23, 3:00 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:40 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:40 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:35 PM | 1 week ago |
| SMA: Bearish | Oct 23, 1:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 12:55 PM | 1 week ago |
| SMA: Bearish | Oct 23, 12:15 PM | 1 week ago |
| SMA: Bullish | Oct 23, 11:15 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:00 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:50 AM | 1 week ago |
News
3 days ago prnewswire.com
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close…
1 week ago seekingalpha.com
Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine
Rigel Pharmaceuticals is evolving into a multi-product oncology platform, leveraging Big Pharma castoffs to drive growth beyond its ITP legacy. VEPPANU's U.S. launch targets a $1B ESR1-mutated breast…
-
1 week ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $85 price target.
1 week ago prnewswire.com
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and…
1 month ago prnewswire.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.…
1 month ago defenseworld.net
Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN)
Rigel Pharmaceuticals (NASDAQ: RIGL - Get Free Report) and Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) are both healthcare companies, but which is the better investment? We will…
2 months ago prnewswire.com
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today…
2 months ago defenseworld.net
18,800 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Canada Pension Plan Investment Board
Canada Pension Plan Investment Board acquired a new position in Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the second quarter, according to the company in its most recent disclosure with the…
2 months ago defenseworld.net
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL
Connor Clark and Lunn Investment Management Ltd. bought a new stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) in the undefined quarter, according to its most recent disclosure with the…
-
2 months ago benzinga.com
Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49
Piper Sandler analyst Allison Bratzel maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $40 to $49.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85
HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $57 to $85.
-
2 months ago benzinga.com
Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. Prescription
VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to…
2 months ago prnewswire.com
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO,…
2 months ago seekingalpha.com
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth…
2 months ago seekingalpha.com
Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)
Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product…
2 months ago seekingalpha.com
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Rigel Pharmaceuticals Q2 Earnings Call Highlights
Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy…
2 months ago zacks.com
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $3.28 per share a year ago.
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
-
2 months ago benzinga.com
Rigel Pharmaceuticals Raises FY2026 Sales Guidance from $275.000M-$290.000M to $285.000M-$295.000M vs $308.461M Est
Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2026 sales outlook from $275.000 million-$290.000 million to $285.000 million-$295.000 million vs $308.461 million estimate.
-
2 months ago benzinga.com
Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.62 by 41.94 percent. This is a 73.17 percent decrease over earnings…
2 months ago prnewswire.com
Rigel Reports Second Quarter 2026 Financial Results
Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 million Expanded…
3 months ago prnewswire.com
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close…
3 months ago prnewswire.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.…
4 months ago prnewswire.com
Rigel Appoints Board Member Alison L. Hannah, M.D.
Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the company SOUTH SAN…
4 months ago seekingalpha.com
A Look At The Transformation Around Rigel Pharmaceuticals
Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just over $600 million. RIGL's growth strategy pivots on the Veppanu licensing deal, supplementing…
-
4 months ago benzinga.com
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM…
4 months ago prnewswire.com
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57 price target.
-
5 months ago benzinga.com
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $69 to $81.
5 months ago benzinga.com
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE)…
5 months ago benzinga.com
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.
-
5 months ago benzinga.com
Arvinas, Pfizer Strike Up To $405M VEPPANU Licensing Deal With Rigel
Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE:PFE) have entered into a license agreement with Rigel…
-
5 months ago benzinga.com
Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license…
-
5 months ago benzinga.com
Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69
Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and lowers the price target from $71 to $69.
-
6 months ago benzinga.com
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M vs $284.068M Est
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million vs $284.068 million estimate.
6 months ago benzinga.com
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Rigel Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
-
6 months ago benzinga.com
Rigel Pharmaceuticals Q1 EPS $0.44 Misses $0.76 Estimate, Sales $58.800M Miss $62.392M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.76 by 42.11 percent. This is a 30.16 percent decrease over…
-
6 months ago benzinga.com
Eli Lilly To Terminate Rigel Collaboration On RIPK1 Inhibitor Ocadusertib Effective June 15, 2026; Does Not Expect Future Milestones Or Royalties Under Agreement After Termination
Termination of a Material Definitive Agreement.On April 16, 2026, Rigel Pharmaceuticals, Inc. ("Rigel") received written notice from Eli Lilly and Company ("Lilly") of Lilly's election to terminate…
-
7 months ago benzinga.com
FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Under Evaluation
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
-
7 months ago benzinga.com
Rigel Pharmaceuticals Publishes Final Data From Phase 1/2 ARROW Trial Of Pralsetinib To Treat Metastatic Rearranged During Transfection Fusion-Positive Non-Small Cell Lung Cancer
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
8 months ago benzinga.com
Nasdaq Surges Over 1%; ISM Services PMI Tops Views
U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.
-
8 months ago benzinga.com
Rigel Pharmaceuticals Affirms FY2026 Sales Guidance of $275.000M-$290.000M
Rigel Pharmaceuticals (NASDAQ:RIGL) affirms FY2026 sales outlook from $275.000 million-$290.000 million to $275.000 million-$290.000 million.
8 months ago benzinga.com
Earnings Summary: Rigel Pharmaceuticals Q4
Earnings Summary: Rigel Pharmaceuticals Q4
-
8 months ago benzinga.com
Rigel Pharmaceuticals Q4 Adj. EPS $1.12 Misses $1.25 Estimate, Sales $69.802M Beat $68.701M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.12 per share which missed the analyst consensus estimate of $1.25 by 10.18 percent. This is a 40 percent increase over earnings…
-